Paolo Pozzilli, MD
Campus Bio-Medico di Roma (UCBM) Policlinico Universitario, Rome, Italy, 00128 · University Campus Bio-medico · Head, Endocrinology and Diabetes Unit, Campus Bio-Medico University of Rome
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paolo Pozzilli, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05368402 · Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.Dompé Farmaceutici S.p.A · terminated · Type 1 Diabetes · principal investigator
- Ph3NCT02730949 · D-chiro-Inositol in Overweight Type 1 Diabetes PatientsCampus Bio-Medico University · completed · Type 1 Diabetes · principal investigator
- Ph3NCT01762644 · The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes PatientsPerle Bioscience, Inc. · withdrawn · Type 1 Diabetes · principal investigator
- Ph3NCT00615264 · Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes PatientsAndromeda Biotech Ltd. · completed · Type 1 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.